Exelixis, Inc. (NASDAQ:EXEL) will hold its 3Q20 earnings conference call with the financial community on 5th November 2020 at 5:00 PM Eastern Time.
The conference call will be webcast live on Internet at www.exelixis.com
Earnings Expectation
Exelixis, Inc. is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, EXEL to report 3Q20 income of $ 0.01 per share. For the full year, analysts anticipate top line of $ 922.00 million, while looking forward to income of $ 0.37 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 900.00 million ~ $ 950.00 million
Click Here For More Historical Outlooks Of Exelixis, Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The companys products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
